Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Diagnostic imaging of the diabetic foot: an EANM evidence-based guidance
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-024-06693-y
document
PURPOSE: Consensus on the choice of the most accurate imaging strategy in diabetic foot infective and non-infective complications is still lacking. This document provides evidence-based recommendations, aiming at defining which imaging modality should be preferred in different clinical settings. METHODS: This working group includes 8 nuclear medicine physicians appointed by the European Association of Nuclear Medicine (EANM), 3 radiologists and 3 clinicians (one diabetologist, one podiatrist and one infectious diseases specialist) selected for their expertise in diabetic foot. The latter members formulated some clinical questions that are not...
Chiara Lauri, Edel Noriega-Álvarez, Riddhika M Chakravartty, Olivier Gheysens, Andor W J M Glaudemans, Riemer H J A Slart, Thomas C Kwee, Frédéric Lecouvet, Emmanouil Panagiotidis, Jules Zhang-Yin, Jose Luis Lazaro Martinez, Benjamin A Lipsky, Luigi Uccioli, Alberto Signore
Heliyon medical imaging: Shaping the future of health
Published in: Heliyon
Access to document
10.1016/j.heliyon.2024.e32395
document
Andor W.J.M. Glaudemans, Tuan D. Pham
Using machine learning to improve the diagnostic accuracy of the modified Duke/ESC 2015 criteria in patients with suspected prosthetic valve endocarditis: a proof of concept study
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-024-06774-y
document
Introduction: Prosthetic valve endocarditis (PVE) is a serious complication of prosthetic valve implantation, with an estimated yearly incidence of at least 0.4-1.0%. The Duke criteria and subsequent modifications have been developed as a diagnostic framework for infective endocarditis (IE) in clinical studies. However, their sensitivity and specificity are limited, especially for PVE. Furthermore, their most recent versions (ESC2015 and ESC2023) include advanced imaging modalities, e.g., cardiac CTA and [18F]FDG PET/CT as major criteria. However, despite these significant changes, the weighing system using major and minor criteria has remained...
D. ten Hove, R. H.J.A. Slart, A. W.J.M. Glaudemans, D. F. Postma, A. Gomes, L. E. Swart, W. Tanis, P. P. van Geel, G. Mecozzi, R. P.J. Budde, K. Mouridsen, B. Sinha
The Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases: An Updated Systematic Review
Published in: Pharmaceuticals
Access to document
10.3390/ph17060716
document
The role of fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) is emerging for the assessment of non-oncological diseases, such as inflammatory and infectious diseases, even if the evidence in the literature is still in its initial phases. We conducted a systematic search of Scopus, PubMed/MEDLINE, Embase, and Cochrane library databases for studies published before 31 December 2023 reporting infectious and inflammatory disease imaging with FAPI PET/CT. We included twenty-one studies for a total of 1046 patients. The most frequent disease studied was lung interstitial disease,...
Domenico Albano, Alessio Rizzo, Riemer H.J.A. Slart, Søren Hess, Edel Noriega-Álvarez, Cristina Gamila Wakfie-Corieh, Lucia Leccisotti, Andor W.J.M. Glaudemans, Olivier Gheysens, Giorgio Treglia
11C-Methionine uptake in meningiomas after stereotactic radiotherapy.
Published in: ANNALS OF NUCLEAR MEDICINE
Access to document
10.1007/s12149-024-01932-6
document
OBJECTIVE: 11C-Methionine positron emission tomography (MET-PET) is used for stereotactic radiotherapy planning in meningioma patients. The role of MET-PET during subsequent follow-up (FU) is unclear. We analyzed the uptake of 11C-Methionine before and after stereotactic radiotherapy (SRT) in patients with a complex meningioma and investigated if there was a difference between patients with progressive disease (PD) and stable disease (SD) during FU. METHODS: This retrospective study investigates 62 MET-PETs in 29 complex meningioma patients. Standardized uptake value (SUV) max and SUV peak tumor-to-normal ratios (T/N-ratios) were calculated, comparing...
Hanne-Rinck Jeltema, Bart R J van Dijken, Katalin Tamási, Gea Drost, Mart A A M Heesters, Anouk van der Hoorn, Andor W J M Glaudemans, J Marc C van Dijk